Previous 10 | Next 10 |
2023-04-28 03:11:10 ET Specialty cancer diagnostics company Precipio ( NASDAQ: PRPO ) has been granted a 180-day extension by Nasdaq to allow the company to meet the required minimum $1.00 per share closing bid price for 10 consecutive business days. The stoc...
NEW HAVEN, Conn., April 27, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announces notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum $1.00 per sh...
NEW HAVEN, Conn., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced a 4-year agreement with a new customer to bring HemeScreen™ technology into their lab. Based on volume information provided by the customer...
Precipio, Inc. (PRPO) Q3 2022 Earnings Conference Call November 14, 2022 05:00 PM ET Company Participants Ilan Danieli - Chief Executive Officer Conference Call Participants Presentation Operator Welcome to the Precipio Shareholder Third Quart...
NEW HAVEN, Conn., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) presented at the annual 2022 AMP conference a poster presentation of the results of a groundbreaking study, conducted in collaboration with faculty ...
NEW HAVEN, Conn., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q3-2022 shareholder update call on Monday, November 14 th at 5:00 PM ET. The call will include updates on the Company’s cur...
NEW HAVEN, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , has signed a distribution agreement for HemeScreen with a major distribution partner (name withheld as per partner’s policy). Following an upcomin...
NEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , welcomes Sharon Robins as the Company’s Senior Director of Laboratory & Hospital Sales for the Product’s Division. As the Company launch...
NEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces the launch of its second generation of HemeScreen panels. Precipio’s customers using HemeScreen in their laboratory will have the option ...
Precipio, Inc. (PRPO) Q2 2022 Earnings Conference Call August 15, 2022, 17:00 ET Company Participants Ilan Danieli - Founder, President, CEO & Director Conference Call Participants Presentation Operator Welcome to the Precipio Shareholder ...
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Patholog...
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted...
NEW HAVEN, Conn., June 12, 2024 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately today no later than 11pm Eastern Time. In order to e...